

Product Data Sheet

Product Name: MSH Release-Inhibiting Factor (trifluoroacetate salt)

Cat. No.: GC91914

Chemical Properties

Cas. No.

Chemical Name L-prolyl-L-leucyl-glycinamide, trifluoroacetate salt

SMILES O=C([C@@H](NC([C@H]1NCCC1)=O)CC(C)C)NCC(N)=O.FC(F)(C(O)=O)F


Formula $C_{13}H_{24}N_4O_3 \cdot XCF_3COOH$ M.Wt 284.4

Solubility Water: 1 mg/ml Storage $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

MSH release-inhibiting factor (MSH-R-IF) is a hypothalamic tripeptide that binds to rat striatum ($K_d = 4.69$ nM) and has diverse biological activities.^{1,2,3,4} *In vivo*, MSH-R-IF (0.1 mg/kg) decreases immobility of mice in the forced swim test, indicating antidepressant-like activity.² MSH-R-IF (20 mg/kg) increases striatal concentration of dopamine and the dopamine metabolites DOPAC, 3-methoxy tyramine (3-MT), and homovanillic acid (HVA) in a mouse model of Parkinson's disease induced by MPTP.³ It decreases vacuous chewing movements induced by haloperidol in a rat model

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

of tardive dyskinesia when administered at a dose of 2 mg/kg.⁴ MSH-R-IF also has anti-opiate effects, reversing analgesia induced by morphine and an enkephalin in mice in a radiant heat tail-flick assay.¹

References:

- [1]. Pan, W., and Kastin, A.J. From MIF-1 to endomorphin: The Tyr-MIF-1 family of peptides. *Peptides* 28(12):2411-2434 (2007).
- [2]. Kastin, A.J., Abel, D.A., Ehrensing, R.H., et al. Tyr-MIF-1 and MIF-1 are active in the water wheel test for antidepressant drugs. *Pharmacol. Biochem. Behav.* 21(5):767-771 (1984).
- [3]. Marcotte, E.R., Chugh, A., Mishra, R.K., et al. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH₂ (PLG, MIF-1). *Peptides* 19(2):403-406 (1998).
- [4]. Sharma, S., Paladino, P., Gabriele, J., et al. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia. *Peptides* 24(2):313-319 (2003).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA